

# Supporting Information

for *Adv. Sci.*, DOI 10.1002/advs.202203699

The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer

*Yutian Zou, Feng Ye, Yanan Kong, Xiaoqian Hu, Xinpei Deng, Jindong Xie, Cailu Song, Xueqi Ou, Song Wu, Linyu Wu, Yi Xie, Wenwen Tian, Yuhui Tang, Chau-Wei Wong, Zhe-Sheng Chen\*, Xinhua Xie\* and Hailin Tang\**

### **Supporting Information**

**The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer**

Yutian Zou<sup>1,†</sup>; Feng Ye<sup>1,†</sup>; Yanan Kong<sup>1,†</sup>; Xiaoqian Hu<sup>2</sup>; Xinpei Deng<sup>1</sup>; Jindong Xie<sup>1</sup>; Cailu Song<sup>1</sup>; Xueqi Ou<sup>1</sup>; Song Wu<sup>1</sup>; Linyu Wu<sup>1</sup>; Yi Xie<sup>1</sup>; Wenwen Tian<sup>1</sup>; Yuhui Tang<sup>1</sup>; Chau-Wei Wong<sup>1</sup>; Zhe-Sheng Chen<sup>3,\*</sup>; Xinhua Xie<sup>1,\*</sup>; Hailin Tang<sup>1,\*</sup>

#### **Author Affiliations:**

<sup>1</sup> Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China;

Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

<sup>2</sup> School of Biomedical Sciences, Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

<sup>3</sup> College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.

#### **\* Corresponding authors:**

Hailin Tang (tanghl@sysucc.org.cn), Xinhua Xie (xiexh@sysucc.org.cn):

Sun Yat-sen University Cancer Center,

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, China.

Zhe-Sheng Chen (chenz@stjohns.edu):

Department of Pharmaceutical Sciences, College of Pharmaceutical Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.

#### **Supplementary Figures**



**Supplementary Figure 1. Quality control of the single-cell sequencing data.**

**(a-c)** The violin plots showing the number of genes (nGene) detected, percent of mitochondrial derived transcripts (percent.mito), and number of unique molecular identifiers (nUMI). **(d-f)** t-SNE plots of single cells profiled colored by nGene, percent.mito, and nUMI. **(g-i)** The violin plots showing the distribution of nGene, percent.mito, and nUMI in each cell cluster. **(g-i)** The violin plots showing the distribution of nGene, percent.mito, and nUMI in each sample.



**Supplementary Figure 2. Tumor ecosystem of breast cancer liver and brain metastases characterized by single-cell transcriptomic sequencing**

**(a)** The relative proportions of each major cell subtype in different samples. **(b)** Highlight t-SNE plots exhibiting the distribution of each major cell type. **(c)** Feature plots showing the normalized expression of immune checkpoint genes in each major cell subtype. **(d)** Dot plot showing the expression level of immune checkpoint genes in each major cell type.



**Supplementary Figure 3. Identification and validation of KLF5 as a druggable target for inhibiting breast cancer metastasis.**

**(a)** Expression level of *KLF5* mRNA in different molecular subtypes of breast cancer in TCGA cohort. **(b)**  Kaplan-Meier analysis of the distant metastasis-free survival and overall survival of breast cancer patients

with *KLF5* high or low expression in public database cohorts. **(c-d)** Transwell migration assay revealed the effect of KLF5 inhibitor (ML264, 5 μM) in inhibiting the metastatic ability of MDA-MB-231 and MCF-7 breast cancer cells. Representative graphs and quantification are showed. Scale bar = 100 μm. **(e-f)** Wound healing assay revealed the effect of KLF5 inhibitor (ML264, 5 μM) in inhibiting the migration ability of MDA-MB-231 and MCF-7 breast cancer cells. Representative graphs and quantification are showed. Scale bar = 100 μm. **(g-h)** Colony formation assay revealed the effect of KLF5 inhibitor (ML264, 5 μM) in inhibiting the colonize ability of MDA-MB-231 and MCF-7 breast cancer cells. Representative graphs and quantification are showed.



### **Supplementary Figure 4. Landscape of lymphocytes and innate lymphoid cells in breast cancer liver and brain metastases**

**(a)** Feature plots showing the normalized expression of canonical marker genes in each T cell and NK cell subcluster. **(b)** The relative proportions of each T cell subtype and B cell subtype in liver and brain metastasis of breast cancer. **(c)** Cytotoxicity and dysfunction of each T cell and NK cell cluster was analyzed and quantified by gene signature scores. **(d)** The expression of most varied genes involved in the CD8+ T cell state transition are showed. **(e)** The expression of most varied genes involved in the B cell state transition are showed. **(f)** Heatmap showing the number of cell-cell interactions between lymphocytes and cancer cells, predicted by CellphoneDB 2 method. **(g)** Dot plot showing the ligand-receptor pairs of chemokines between cancer cells and each lymphocyte cluster, predicted by CellphoneDB 2 method. **(h)** Dot plot showing the other ligand-receptor pairs between cancer cells and each lymphocyte cluster, predicted by CellphoneDB 2 method.



**Supplementary Figure 5. Characterization of the tumor microenvironment components among different metastatic sites of breast cancer using bulk transcriptome data.**

**(a)** Heatmap of the tumor microenvironment components calculated by xCell algorithm among different metastatic sites in GEO datasets (GSE56493, GSE12276, GSE46141, and GSE173661). **(b)** Boxplots of the abundance of immune cells among different metastatic sites in GEO datasets (GSE56493, GSE12276, GSE46141, and GSE173661). \*\*\*\* Means P < 0.0001; \*\*\* Means P < 0.001; \*\* Means P < 0.01; \* Means P  $< 0.05$ .



## **Supplementary Figure 6. Characterization of the immune checkpoint genes and immune cells among different metastatic sites of breast cancer using bulk transcriptome data.**

**(a)** Bubble plot of the relationship between immune checkpoint genes and immune cells in different metastatic

sites of breast cancer. **(b)** Boxplots of the expression of immune checkpoint genes among different metastatic sites of breast cancer in GEO datasets (GSE56493, GSE12276, GSE46141, and GSE173661). \*\*\*\* Means P < 0.0001; \*\*\* Means P < 0.001; \*\* Means P < 0.01; \* Means P < 0.05. **(c)** Correlation between the expression of each immune checkpoint.





**(a)** Correlation between specific immune effector cells (CD8+Tem and NK cell) and other tumor microenvironment cells in metastatic lesions of breast cancer (GEO dataset cohorts were analyzed, including GSE56493, GSE12276, GSE46141, and GSE173661). **(b)** Correlation between tumor microenvironment cells and immune checkpoint genes in metastatic lesions of breast cancer (GEO dataset cohorts were analyzed, including GSE56493, GSE12276, GSE46141, and GSE173661).



**Supplementary Figure 8. Characterization of immunosuppressive myeloid cell in the tumor microenvironment**

**(a)** Violin plot comparing the expression level of phagocytic inhibitory gene (*SIRPA*) and immune checkpoint genes in M1-like and M2-like tumor-associated macrophages (TAMs). **(b)** Dot plot showing the expression

level of immune checkpoint genes in each TAM subclusters. **(c)** The expression of most varied genes involved in the TAM state transition are showed. **(d)** RNA velocity analysis was performed to investigate developmental lineages and cellular dynamics of TAMs. **(e)** Monocle pseudotime trajectory analysis of dendritic cells (DCs) with high variable genes. Each dot on the pseudotime curve represents one single cell, which is colored corresponding to its cluster label. **(f)** The expression of most varied genes involved in the DC state transition are showed. **(g)** The differentially expressed genes along with the DC pseudotime curve is showed in hierarchical heatmap.



**Supplementary Figure 9. Diversity of cancer-associated fibroblasts (CAFs), endothelial cells (ECs) and mural cells (MCs) in the tumor microenvironment**

**(a)** The relative proportions of each stromal cell subcluster in liver and brain metastasis of breast cancer. **(b)** 

The relative proportions of cancer-associated fibroblast (CAF) subcluster in liver and brain metastasis of breast cancer. **(c)** The relative proportions of each endothelial cell (EC) subcluster in liver and brain metastasis of breast cancer. **(d)** The relative proportions of each mural cell (MC) subcluster in liver and brain metastasis of breast cancer. **(e)** RNA velocity analysis was performed to investigate developmental lineages and cellular dynamics of CAFs, ECs, and MCs. **(f)** Violin plot showing the expression level of immune checkpoint genes in each stromal cell subtype. **(g)** Heatmap showing the number of cell-cell interactions between CAFs and cancer cells, predicted by CellphoneDB 2 method. **(h)** Heatmap showing the number of cell-cell interactions between ECs and cancer cells. **(i)** Heatmap showing the number of cell-cell interactions between mural cells and cancer cells. **(j-l)** The potential biological functions and relevant signaling pathway of each CAF, EC, and MC subcluster was evaluated by GO and KEGG analysis.



## **Supplementary Figure 10. Cell clustering and functional annotation of organ-specific resident cells in breast cancer liver and brain metastases**

**(a)** Re-clustering organ-specific resident cells and visualizing the profile of each cell subtype via t-SNE plot.

**(b)** Feature plots showing the normalized expression of canonical marker genes in each resident cell subcluster.

**(c)** The relative proportions of each resident cell cluster in liver and brain metastasis of breast cancer. **(d)** The heatmap of the expression level of top 10 differentially expressed genes among thirteen subclusters of resident cells. **(e)** Dot plot shows the expression level of canonical marker gene across all resident cell subtypes. **(f)**  Dot plot shows the expression level of immune checkpoint genes across all resident cell subtypes. **(g)** Violin plot showing the expression level of immune checkpoint genes in each resident cell subtype. **(i)** The potential biological functions and relevant signaling pathway of each resident cell subcluster was evaluated by GO and KEGG analysis. **(h)** Feature plots showing the normalized expression of immune checkpoint genes in each resident cell subcluster.



**Supplementary Figure 11. Clonal evolution analysis of oligodendrocytes in breast cancer brain metastasis**

**(a)** Monocle pseudotime trajectory analysis of oligodendrocytes with high variable genes. Each dot on the pseudotime curve represents one single cell, which is colored corresponding to its cluster label. **(b)** The density stream of oligodendrocytes clonal evolution. **(c)** The differentially expressed genes along with the oligodendrocyte pseudotime curve is showed in hierarchical heatmap. **(d)** The expression of most varied genes involved in the oligodendrocyte state transition are showed. **(e-f)** RNA velocity analysis was performed to investigate developmental lineages and cellular dynamics of oligodendrocytes.



**Supplementary Figure 12. Cell-cell communication network between resident cells and cancer cells in breast cancer liver and brain metastasis**

**(a)** Dot plot showing the ligand-receptor pairs of cell growth factors between cancer cells and each resident cell cluster in liver metastasis of breast cancer, predicted by CellphoneDB 2 method. **(b)** Dot plot showing the other significant ligand-receptor pairs between cancer cell and each resident cell cluster in liver metastasis of breast cancer. **(c)** Dot plot showing the ligand-receptor pairs of cell growth factors between cancer cells and each resident cell cluster in brain metastasis of breast cancer. **(d)** Heatmap showing the number of cell-cell interactions between resident cells and cancer cells in brain metastasis of breast cancer, predicted by CellphoneDB 2 method. **(e)** Dot plot shows the expression level of cell growth factor genes across all resident cell subtypes.

**Supplementary Table 1: Clinical information for breast cancer patients analyzed by scRNAseq in this study.**



# **Supplementary Table 2: Pathological and immunohistochemical information for breast cancer patients analyzed by scRNA-seq in this study.**

